Phase III double blind study of Bortezomib and Dex in combination with Venetoclax or Placebo in R/R MM

Administered By

Duke Cancer Institute

Awarded By

AbbVie Inc.

Contributors

Gasparetto, Cristina Principal Investigator

Start/End

October 1, 2016 - September 30, 2021